TY - JOUR
T1 - Urea-cycle disorders as a paradigm for inborn errors of hepatocyte metabolism
AU - Mian, Asad
AU - Lee, Brendan
N1 - Funding Information:
We thank O. Hernandez for administrative assistance and S. Carter for clinical assistance. We are supported by the NIH (DK56787 and DK54450), the Baylor College of Medicine Child Health Research Center, the Mental Retardation Research Center (HD24064) and the Texas Children's Hospital General Clinical Research Center (RR00188). This review is dedicated to the memory of Dr Peter Reeds.
PY - 2002/12
Y1 - 2002/12
N2 - Urea-cycle disorders (UCDs) are a group of inborn errors of hepatocyte metabolism that are caused by the loss of enzymes involved in the process of transferring nitrogen from ammonia to urea, via the urea cycle (UC). Recent genetic analyses of inherited disorders that present with hyperammonemia demonstrate the function of cellular transporters that regulate the availability of UC intermediates. The regulation of UC intermediates, such as arginine, could have far reaching implications on nitric-oxide synthesis and vascular tone. Hence, each UCD and UC-related disorder constitutes a unique gene-nutrient interaction that is crucial for postnatal homeostasis. Recent advances in the diagnosis and management of UCDs include the application of in vivo metabolic-flux measurements. Cumulative morbidity is still high despite dietary and pharmacological therapies and, hence, both cell and gene therapies are being pursued as possible long-term corrective treatments. Although gene-replacement therapy has suffered recent clinical setbacks, new vector developments offer hope for the treatment of cell-autonomous defects of hepatocyte metabolism.
AB - Urea-cycle disorders (UCDs) are a group of inborn errors of hepatocyte metabolism that are caused by the loss of enzymes involved in the process of transferring nitrogen from ammonia to urea, via the urea cycle (UC). Recent genetic analyses of inherited disorders that present with hyperammonemia demonstrate the function of cellular transporters that regulate the availability of UC intermediates. The regulation of UC intermediates, such as arginine, could have far reaching implications on nitric-oxide synthesis and vascular tone. Hence, each UCD and UC-related disorder constitutes a unique gene-nutrient interaction that is crucial for postnatal homeostasis. Recent advances in the diagnosis and management of UCDs include the application of in vivo metabolic-flux measurements. Cumulative morbidity is still high despite dietary and pharmacological therapies and, hence, both cell and gene therapies are being pursued as possible long-term corrective treatments. Although gene-replacement therapy has suffered recent clinical setbacks, new vector developments offer hope for the treatment of cell-autonomous defects of hepatocyte metabolism.
UR - http://www.scopus.com/inward/record.url?scp=0036892285&partnerID=8YFLogxK
U2 - 10.1016/S1471-4914(02)02437-1
DO - 10.1016/S1471-4914(02)02437-1
M3 - Review article
C2 - 12470992
AN - SCOPUS:0036892285
SN - 1471-4914
VL - 8
SP - 583
EP - 589
JO - Trends in Molecular Medicine
JF - Trends in Molecular Medicine
IS - 12
ER -